Thomsen-Friedenreich (TF) Antigen Vaccine Development Service
Your Satisfaction in TF Antigen Vaccine Development Is Our Commitment
Thomsen-Friedenreich (TF) antigen (β-d-Galp-(1,3)-α-D-GalNAcp) is a class of tumor-associated carbohydrate antigens (TACAs) that is usually linked to serine or threonine residues on mucins. TF antigens are usually aberrantly expressed on the surface of cancer cells, especially in breast and prostate cancer. CD BioGlyco has developed monophosphate lipid derivatives coupled to semisynthetic TF antigens to provide new avenues for potential Carbohydrate Click-based Sugar-conjugated Vaccine development. Moreover, Our talent team provides other GlycoCLICK™-based Vaccine Development Services such as Triazole Skeleton-based Vaccine and Multivalent Glycopeptide-lipopeptide Vaccine.
- Carbohydrate Click Service
We provide services for the expression of high-purity lipids from Escherichia coli, which effectively avoids the risk of contamination by other reagents. Then, we offer the service of synthesizing lipid derivatives (azide, alkyne, double bond, and thiol precursors) carrying clickable portions by click chemistry.
- Modification Service
Our research team find that TACAs (e. g. Truncated Glycan Tn Antigen, Sialyl-Tn, and GM3) are appropriately modified to improve their immunogenicity. Therefore, we provide a range of antigen-modifying services including fluorine-containing acyl group modification, clustered format modification, multimeric construct modification, and C-linked analog modification. In addition, We provide testing services for the immunological effects of the modified antigens.
- Immune Assessment Service
- We provide animal model-building services according to the special development needs of our clients. We provide mouse culture, vaccination, observation, and analysis services.
- To determine the role of inoculated mouse serum in recognizing natural TF antigens in cancer cells, we use flow cytometry to analyze the binding and affinity of immune serum antibodies to cancer cells expressing natural TF antigens.
- To determine whether the immune response triggered by the TF antigen vaccine is effective for cancer immunity, we analyze the complement-dependent and concomitant ability of antisera from inoculated mice to mediate tumor cell killing.
- We provide serological assays by using enzyme-linked immunosorbent assay (ELISA), complement-dependent cytotoxicity (CDC) assays, and lymphocyte proliferation assays.
Publication
Technology: Matrix-assisted laser desorption ionization-time-of-flight mass spectrometry (MALDI-TOF MS), Nuclear magnetic resonance (NMR)
Journal: Journal of Medicinal Chemistry
Published: 2017
IF: 8.039
Results: In this work, we have established a generalized method for inserting clickable portions (azide, alkyne, double bond, and thiol precursors) into monophosphoryl lipid A obtained from E. coli. We successfully used this method to synthesize a thiol-containing derivative of TF antigen, which was then coupled to the clickable lipid-derivative carrying the double-bonded portion by UV-mediated thiol-alkene reaction. Furthermore, immunoreactivity assessment of the lipid A-TF antigen coupling showed that the coupling effectively induced immunomodulation.
Fig.1 MALDI-TOF mass spectrum of the crude reaction mixture. (Ziaco, et al., 2017)
Advantages of Us
- Covalent coupling of the immunostimulatory fraction to TF antigen significantly enhances the immunogenicity of TF antigen and produces vaccine candidates with high selectivity
- The semi-synthetic strategy we use avoids long and complex procedures and a large number of chemical steps.
- Our professional developers with rich experience in vaccine development quickly and accurately help our clients complete their projects.
CD BioGlyco customizes the vaccine synthesis routes and immunization assessment protocol according to the project characteristics. To learn more information about TF antigen vaccine development, please feel free to contact us.
References
- Sun, S.; et al. Synthesis and evaluation of glycoconjugates comprising N-acyl-modified Thomsen-Friedenreich antigens as anticancer vaccines. ChemMedChem. 2016, 11(10): 1090-1096.
- Ziaco, M.; et al. Development of clickable monophosphoryl lipid A derivatives toward semisynthetic conjugates with tumor-associated carbohydrate antigens. J Med Chem. 2017, 60(23): 9757-9768.
For research use only. Not intended for any clinical use.
Related Services
